Addex Therapeutics Ltd (Addex) is a biopharmaceutical company that develops and commercialize orally available, small molecule drugs, called allosteric modulators against diseases with high unmet medical needs. It develops therapeutic compounds for the treatment of rare diseases with orphan drug designation potential for the dipraglurant in PD-LID.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Addex R&D efforts focus on the development of small-molecule pharmaceutical products based on its allosteric modulator platform. The proprietary drug candidates in clinical and preclinical stages are being developed by the company and its partners to treat diseases that lack approved therapies or require better treatment options. These diseases comprise levodopa-induced dyskinesia associated with Parkinson's disease (PD-LID), epilepsy, addiction (including alcohol use disorder), Charcot-Marie-Tooth type 1A neuropathy (CMT1A), as well as other neurodegenerative diseases. - In FY2022, the company spent CHF14.6 million on its R&D activities, which increased by 14% YoY.